Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial.
Jänne, P van den Heuvel, M Barlesi, F Cobo, M Mazieres, J Crinò, L Orlov, S Blackhall, Fiona H Wolf, J Garrido, P
Jänne, P
van den Heuvel, M
Barlesi, F
Cobo, M
Mazieres, J
Crinò, L
Orlov, S
Blackhall, Fiona H
Wolf, J
Garrido, P
Citations
Altmetric:
Abstract
There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.
Description
Date
2017
Publisher
Collections
Keywords
Type
Article
Citation
Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial. 2017, 317 (18):1844-1853 JAMA